CNW/ - Hoffmann-La Roche Limited (Roche Canada) is proud to announce that Health Canada has granted market authorization for ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

BASEL, Switzerland—Multiple randomized trials presented last week at the European Stroke Organisation Conference (ESOC) 2024 have bolstered the case that tenecteplase (TNK) is an effective—if not ...

THURSDAY, March 20, 2025 (HealthDay News) -- A newly approved clot- busting drug for stroke works as well as a decades-old medication still used by most U.S. hospitals, and can be delivered even more ...

Please provide your email address to receive an email when new articles are posted on . Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset ...

Stroke survivors were more likely to have little or no disability after 90 days if a clot was removed from a large brain artery followed by the injection of the clot-dissolving medication tenecteplase ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

Early diagnosis and timely treatment by doctors in taluk hospitals gave a new lease of life to 7,815 patients with cardiac complications. Of these, doctors were able to save the lives of 1,106 by ...